Annual EBITDA
-$241.49 M
-$64.63 M-36.54%
December 31, 2024
Summary
- As of March 14, 2025, NAMS annual EBITDA is -$241.49 million, with the most recent change of -$64.63 million (-36.54%) on December 31, 2024.
- During the last 3 years, NAMS annual EBITDA has fallen by -$200.12 million (-483.74%).
- NAMS annual EBITDA is now -3533.17% below its all-time high of -$6.65 million, reached on December 1, 2020.
Performance
NAMS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$111.69 M
-$87.85 M-368.51%
December 31, 2024
Summary
- As of March 14, 2025, NAMS quarterly EBITDA is -$111.69 million, with the most recent change of -$87.85 million (-368.51%) on December 31, 2024.
- Over the past year, NAMS quarterly EBITDA has dropped by -$87.85 million (-368.51%).
- NAMS quarterly EBITDA is now -368.51% below its all-time high of -$23.84 million, reached on September 30, 2024.
Performance
NAMS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$241.49 M
-$60.71 M-33.58%
December 31, 2024
Summary
- As of March 14, 2025, NAMS TTM EBITDA is -$241.49 million, with the most recent change of -$60.71 million (-33.58%) on December 31, 2024.
- Over the past year, NAMS TTM EBITDA has dropped by -$60.71 million (-33.58%).
- NAMS TTM EBITDA is now -525.30% below its all-time high of -$38.62 million, reached on March 31, 2023.
Performance
NAMS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
NAMS EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -36.5% | -368.5% | -33.6% |
| 3 y3 years | -483.7% | -368.5% | -33.6% |
| 5 y5 years | -3533.2% | -368.5% | -33.6% |
NAMS EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -981.0% | at low | -368.5% | at low | -525.3% | at low |
| 5 y | 5-year | -3533.2% | at low | -368.5% | at low | -525.3% | at low |
| alltime | all time | -3533.2% | at low | -368.5% | at low | -525.3% | at low |
NewAmsterdam Pharma Company NV EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$241.49 M(+36.5%) | -$111.69 M(+368.5%) | -$241.49 M(+33.6%) |
| Sep 2024 | - | -$23.84 M(-53.6%) | -$180.78 M(-11.9%) |
| Jun 2024 | - | -$51.38 M(-5.9%) | -$205.21 M(+6.4%) |
| Mar 2024 | - | -$54.57 M(+7.0%) | -$192.82 M(+9.0%) |
| Dec 2023 | -$176.86 M | -$50.99 M(+5.6%) | -$176.86 M(+40.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2023 | - | -$48.27 M(+23.8%) | -$125.87 M(+62.2%) |
| Jun 2023 | - | -$38.99 M(+1.0%) | -$77.61 M(+101.0%) |
| Mar 2023 | - | -$38.62 M | -$38.62 M |
| Dec 2022 | -$22.34 M(-46.0%) | - | - |
| Dec 2021 | -$41.37 M(+522.4%) | - | - |
| Dec 2020 | -$6.65 M | - | - |
FAQ
- What is NewAmsterdam Pharma Company NV annual EBITDA?
- What is the all time high annual EBITDA for NewAmsterdam Pharma Company NV?
- What is NewAmsterdam Pharma Company NV annual EBITDA year-on-year change?
- What is NewAmsterdam Pharma Company NV quarterly EBITDA?
- What is the all time high quarterly EBITDA for NewAmsterdam Pharma Company NV?
- What is NewAmsterdam Pharma Company NV quarterly EBITDA year-on-year change?
- What is NewAmsterdam Pharma Company NV TTM EBITDA?
- What is the all time high TTM EBITDA for NewAmsterdam Pharma Company NV?
- What is NewAmsterdam Pharma Company NV TTM EBITDA year-on-year change?
What is NewAmsterdam Pharma Company NV annual EBITDA?
The current annual EBITDA of NAMS is -$241.49 M
What is the all time high annual EBITDA for NewAmsterdam Pharma Company NV?
NewAmsterdam Pharma Company NV all-time high annual EBITDA is -$6.65 M
What is NewAmsterdam Pharma Company NV annual EBITDA year-on-year change?
Over the past year, NAMS annual EBITDA has changed by -$64.63 M (-36.54%)
What is NewAmsterdam Pharma Company NV quarterly EBITDA?
The current quarterly EBITDA of NAMS is -$111.69 M
What is the all time high quarterly EBITDA for NewAmsterdam Pharma Company NV?
NewAmsterdam Pharma Company NV all-time high quarterly EBITDA is -$23.84 M
What is NewAmsterdam Pharma Company NV quarterly EBITDA year-on-year change?
Over the past year, NAMS quarterly EBITDA has changed by -$87.85 M (-368.51%)
What is NewAmsterdam Pharma Company NV TTM EBITDA?
The current TTM EBITDA of NAMS is -$241.49 M
What is the all time high TTM EBITDA for NewAmsterdam Pharma Company NV?
NewAmsterdam Pharma Company NV all-time high TTM EBITDA is -$38.62 M
What is NewAmsterdam Pharma Company NV TTM EBITDA year-on-year change?
Over the past year, NAMS TTM EBITDA has changed by -$60.71 M (-33.58%)